Have a feature idea you'd love to see implemented?
Let us know!
BCTX BriaCell Therapeutics Corp
Price (delayed)
$0.7297
Market cap
$26.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.29
Enterprise value
$25.54M
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
Highlights
The EPS has surged by 78% year-on-year and by 22% since the previous quarter
The net income has soared by 76% YoY and by 18% QoQ
BriaCell Therapeutics's quick ratio has plunged by 99% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of BCTX
Market
Valuations
Earnings
Shares outstanding
36.18M
Market cap
$26.4M
Enterprise value
$25.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$4.93M
EBITDA
-$4.85M
Free cash flow
-$24.58M
Per share
Balance sheet
Liquidity
EPS
-$0.29
Free cash flow per share
-$1.49
Book value per share
-$0.13
Revenue per share
$0
TBVPS
$0.34
Total assets
$5.87M
Total liabilities
$8.56M
Debt
$0
Equity
-$2.38M
Working capital
-$3.81M
Debt to equity
0
Current ratio
0.49
Quick ratio
0.12
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46%
Return on equity
N/A
Return on invested capital
-1,609.2%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCTX stock price
How has the BriaCell Therapeutics stock price performed over time
Intraday
-7.52%
1 week
22.64%
1 month
-16.34%
1 year
-84.03%
YTD
-87.53%
QTD
-41.15%
Financial performance
How have BriaCell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$33.33M
Net income
-$4.93M
Gross margin
N/A
Net margin
N/A
The net income has soared by 76% YoY and by 18% QoQ
The company's operating income fell by 43% YoY but it rose by 5% QoQ
Growth
What is BriaCell Therapeutics's growth rate over time
Valuation
What is BriaCell Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 78% year-on-year and by 22% since the previous quarter
The company's equity has surged by 60% QoQ and by 37% YoY
Efficiency
How efficient is BriaCell Therapeutics business performance
BriaCell Therapeutics's ROIC has plunged by 75% from the previous quarter but it has increased by 32% YoY
BCTX's ROA is up by 27% year-on-year but it is down by 22% since the previous quarter
Dividends
What is BCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCTX.
Financial health
How did BriaCell Therapeutics financials performed over time
The total assets is 31% smaller than the total liabilities
BriaCell Therapeutics's quick ratio has plunged by 99% YoY and by 14% from the previous quarter
BriaCell Therapeutics's current ratio has shrunk by 97% YoY and by 40% QoQ
The debt is 100% greater than the equity
The company's equity has surged by 60% QoQ and by 37% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.